Myles C. Cabot
Corresponding Author: Myles C. Cabot
Department of Experimental Therapeutics
John Wayne Cancer Institute
2200 Santa Monica Blvd
Name/email consistency: high
- Ceramide-antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer. Morad, S.A., Levin, J.C., Shanmugavelandy, S.S., Kester, M., Fabrias, G., Bedia, C., Cabot, M.C. Mol. Cancer Ther. (2012)
- Sphingolipid metabolism and drug resistance in hematological malignancies. Gouaze-Andersson, V., Cabot, M.C. Anticancer. Agents. Med. Chem (2011)
- SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. Cabot, M.C., Giuliano, A.E., Han, T.Y., Liu, Y.Y. Cancer Res. (1999)
- The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation. Cabot, M.C., Han, T.Y., Giuliano, A.E. FEBS Lett. (1998)